Share this Page:
Kidney cancer specialists from around the UK have written to the National Institute for Health and Care Excellence (NICE), the government’s health watchdog, to demand the immunotherapy, nivolumab, is made available to NHS patients. In trials of nivolumab, which is used in the treatment of advanced kidney cancer that has stopped responding to treatment, researchers found 55 per cent of the 406 patients given the drug survived beyond two years. From clinical trials in North America, it is believed many could go on to live far longer.
NICE have released their preliminary decision not to allow nivolumab to be used for NHS patients; this has angered kidney cancer specialists, who have written to NICE to demand the approval of nivolumab.